Bevacizumab for Primary Pterygium Treatment

Instituto de Oftalmología Fundación Conde de Valenciana

Status and phase: Completed; Phase 1

Conditions: Pterygium

Treatments: Procedure: Autoconjunctival grafting; Drug: Subconjuntival bevacizumab injection

Study type: Interventional

Funder types: Other

Identifiers

NCT01686529

CC-008-2010

Details and patient eligibility

About

The aim of this study was to investigate the efficacy and safety of subconjunctival bevacizumab application as an adjuvant therapy for primary pterygium.

Enrollment: 49 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with primary pterygium

Exclusion criteria

• Patients with diabetes mellitus
• collagenopathies,
• previous ocular surgeries,
• pregnant or lactating patients

Trial design

49 participants in 3 patient groups

One subconjunctival injection

Experimental group

Description:

Autoconjunctival grafting and one subconjuntival bevacizumab injection (2.5mg/0.1ml) was applied after surgery

Treatment:

Drug: Subconjuntival bevacizumab injection

Procedure: Autoconjunctival grafting

Two subconjuctival injections

Experimental group

Description:

Autoconjunctival grafting and subconjuntival bevacizumab injection (2.5mg/0.1ml) was applied after surgery, with another injection 15 days after surgery

Treatment:

Drug: Subconjuntival bevacizumab injection

Procedure: Autoconjunctival grafting

Conventional treatment

Active Comparator group

Description:

Autoconjunctival grafting without subconjuntival bevacizumab injection

Treatment:

Procedure: Autoconjunctival grafting